Skip to main
IDXX

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories (IDXX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

IDEXX Laboratories has demonstrated exceptional customer retention rates at approximately 97%, enhancing the predictability of its revenue and earnings streams. The company has experienced a robust organic consumables recurring revenue growth, achieving a compound annual growth rate (CAGR) of around 16% from 2016 to 2022. Additionally, the increased adoption of IDEXX’s comprehensive product suite leads to substantial revenue growth, with customers utilizing the total offerings generating 3.5 times higher growth across all testing categories.

Bears say

IDEXX Laboratories is facing a negative outlook due to declining clinical vet visits, which fell by 1.7% year-over-year in Q4'25, indicating a persistent downward trend in the pet healthcare market. Projections for 2026 suggest an additional decline of 200 basis points in pet visits, primarily driven by economic challenges faced by lower-income pet owners. This weakening demand for veterinary services could adversely impact the adoption of IDEXX's diagnostic products and services, ultimately affecting the company's revenue growth and market position.

IDEXX Laboratories (IDXX) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IDEXX Laboratories (IDXX) Forecast

Analysts have given IDEXX Laboratories (IDXX) a Buy based on their latest research and market trends.

According to 10 analysts, IDEXX Laboratories (IDXX) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $706, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $706, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IDEXX Laboratories (IDXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.